▲ Anti-D-Rh0 immunoglobulin (WinRho SD) is the only virally inactivated polyclonal antibody used in preventing the destruction of antibody/platelet complexes in patients with immune thrombocytopenic purpura (ITP)
▲ Its main mechanism of action appears to be via Fc receptor blockade but immunomodulatory mechanisms have also been postulated
▲ Anti-D-Rh0 immunoglobulin achieved response rates ranging from 62 to 92% in children and adults with ITP
▲ In one nonblinded study of children at risk of cerebral haemorrhage, intravenous IgG achieved a greater response than anti-D-Rh0 immunoglobulin as assessed by increases in platelet counts at 72 hours
▲ Increases in platelet counts were greatest in children and in those who had not undergone splenectomy.
KeywordsPlatelet Count Adis International Limited Immune Thrombocytopenic Purpura Drug Profile Intravenous Immune Globulin
Unable to display preview. Download preview PDF.
- 3.Univax WinRho SD shows no adverse events, 26 treatment failures in postmarketing data from Canada; launch planned for late May. FDC Rep Pink Sheet 1995 Apr 3: 21–2Google Scholar